Bank of New York Mellon Corp Has $6.33 Million Position in Amicus Therapeutics, Inc. (FOLD)
Bank of New York Mellon Corp lowered its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 6.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 629,086 shares of the biopharmaceutical company’s stock after selling 43,377 shares during the period. Bank of New York Mellon Corp owned 0.44% of Amicus Therapeutics worth $6,334,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its holdings in Amicus Therapeutics by 5.7% in the first quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock valued at $5,541,000 after buying an additional 41,711 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in Amicus Therapeutics in the second quarter valued at $1,057,000. Geode Capital Management LLC raised its stake in Amicus Therapeutics by 4.7% in the first quarter. Geode Capital Management LLC now owns 1,167,356 shares of the biopharmaceutical company’s stock valued at $8,323,000 after buying an additional 52,003 shares in the last quarter. Morgan Stanley raised its stake in Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after buying an additional 3,055,039 shares in the last quarter. Finally, DORCHESTER WEALTH MANAGEMENT Co acquired a new stake in Amicus Therapeutics in the second quarter valued at $111,000.
COPYRIGHT VIOLATION NOTICE: “Bank of New York Mellon Corp Has $6.33 Million Position in Amicus Therapeutics, Inc. (FOLD)” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-has-6-33-million-position-in-amicus-therapeutics-inc-fold/1604469.html.
A number of analysts have issued reports on FOLD shares. J P Morgan Chase & Co set a $13.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a report on Monday, June 5th. Chardan Capital increased their price objective on Amicus Therapeutics from $12.50 to $17.50 and gave the company a “buy” rating in a report on Thursday, August 10th. Cowen and Company reissued a “buy” rating and set a $16.00 target price (up previously from $10.00) on shares of Amicus Therapeutics in a research report on Tuesday, July 11th. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 16th. Finally, Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $15.25.
Amicus Therapeutics, Inc. (FOLD) opened at 14.99 on Tuesday. The firm’s market cap is $2.47 billion. The firm has a 50-day moving average of $13.75 and a 200 day moving average of $10.39. Amicus Therapeutics, Inc. has a 1-year low of $4.41 and a 1-year high of $16.06.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The company had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. During the same period in the previous year, the business earned ($0.40) EPS. On average, analysts predict that Amicus Therapeutics, Inc. will post ($1.31) EPS for the current year.
In related news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of the firm’s stock in a transaction dated Thursday, July 13th. The stock was acquired at an average price of $12.25 per share, with a total value of $18,375,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.40% of the company’s stock.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.